Dermira, Inc.
DelistedCIK 1557883fmd_1CQ38W52112TYGXKGSRVV2FMBAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2019, 28 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 7 | 7 | 23 | 5 | 42 |
| Cost of revenue | – | – | – | – | – | – | 1 |
| Gross profit | – | – | – | – | – | – | 41 |
| Research and development | 17 | 18 | 31 | 67 | 83 | 104 | 81 |
| Selling, general and administrative | – | – | – | – | 30 | 72 | 173 |
| Total operating expenses | 20 | 22 | 39 | 87 | 113 | 305 | 256 |
| Operating income | (20) | (22) | (32) | (80) | (91) | (300) | (214) |
| Interest expense | – | 0 | 0 | 0 | – | 8 | 16 |
| Interest and investment income | (0) | (0) | 0 | – | – | – | – |
| Other non-operating income (expense) | – | – | – | 1 | 2 | 5 | 8 |
| Income before taxes | (20) | (22) | (32) | (79) | (89) | (303) | (222) |
| Income tax expense | 0 | 0 | 0 | (1) | 0 | 0 | (0) |
| Net income from continuing operations | (20) | (22) | (32) | (78) | (89) | (303) | (222) |
| Net income | (20) | (22) | (32) | (78) | (89) | (303) | (222) |